Drugs
141-160 of 1,326 results
-
-
What’s New and What To Watch For in the Upcoming ACA Open Enrollment Period
This year’s start date in most states is Nov. 1, and consumers may encounter new scams as well as important rule changes.
The Health of the Campaign
Episode 366The 2024 presidential race is taking on a familiar tone — with Democrats accusing Republicans of wanting to ban abortion and repeal the Affordable Care Act and Republicans insisting they have no such plans. Voters will determine whom they believe. Meanwhile, for the second time in a month, a state judge overturned an abortion ban, but few expect the decision to settle the matter. Alice Miranda Ollstein of Politico, Sandhya Raman of CQ Roll Call, and Anna Edney of Bloomberg News join KFF Health News chief Washington correspondent Julie Rovner to discuss these stories and more. Also this week, Rovner interviews KFF Health News’ Lauren Sausser, who reported and wrote the latest KFF Health News-Washington Post “Bill of the Month,” about a teenage athlete whose needed surgery lacked a billing code.
-
Harris Correct That Trump Fell Short on Promise To Negotiate Medicare Drug Prices
The former president instead favored a temporary model that could’ve brought down prices of some prescription drugs, but it was blocked by the courts.
-
Setting the Record Straight on the FDA’s Authority Over Drug Ads
KFF Health News gives readers a chance to comment on a recent batch of stories.
-
How Minnesota Figures Into the Presidential Politics of Insulin Prices
Minnesota led the way on insulin affordability, culminating in 2020 when Gov. Tim Walz signed a law going further to cut costs than other state laws. Now, former President Donald Trump and Vice President Kamala Harris are vying for support from people with diabetes.
Congress Punts to a Looming Lame-Duck Session
Episode 365Congress left Washington for the campaign trail this week, but not before approving a spending bill that expires shortly before Christmas. Lawmakers will be busy after the election working on not just the legislation needed to keep the government running, but also several health programs set to expire. Meanwhile, Republicans continue to downplay abortion as Democrats press it as a campaign issue. Alice Miranda Ollstein of Politico, Lauren Weber of The Washington Post, and Joanne Kenen of Johns Hopkins University and Politico join KFF Health News chief Washington correspondent Julie Rovner to discuss these stories and more.
American Health Under Trump — Past, Present, and Future
Episode 364Dreaming of a Trump victory, Republicans have a wish list of health policy changes — including loosening Affordable Care Act regulations to make cheaper coverage available and ending Medicare drug price negotiations. Meanwhile, after a publicly reported death stemming from a state abortion ban, Vice President Kamala Harris is emphasizing the consequences of Trump’s work to overturn Roe v. Wade. Tami Luhby of CNN, Shefali Luthra of The 19th, and Joanne Kenen of Politico and Johns Hopkins University join KFF Health News senior editor Emmarie Huetteman to discuss these stories and more.
-
California May Regulate and Restrict Pharmaceutical Brokers
California lawmakers are moving to rein in the pharmaceutical middlemen they say drive up costs and limit consumers’ choices. The bill sent to Gov. Gavin Newsom would require pharmacy benefit managers to be licensed in California and would ban some business practices. Newsom vetoed a previous effort three years ago.
By Don Thompson -
-
Perspective
With TV Drug Ads, What You See Is Not Necessarily What You Get
The pharmaceutical industry has invented a new art form: finding ways to make their wares seem like joyous must-have treatments, while often minimizing lackluster efficacy and risks.
-
For Pharma, Trump vs. Harris Is a Showdown Between Two Industry Foes
Vice President Kamala Harris is seen as more aggressive than former President Donald Trump in taking on pharmaceutical companies, but Trump allies say he would also make lowering drug costs a top priority.
-
How Little Denmark Got Homegrown Giant Novo Nordisk To Lower Ozempic Prices
As Congress pushes for Medicare to cover payment for anti-obesity drugs, Denmark — Ozempic maker Novo Nordisk’s home — has limited coverage of the drug after cost overruns “emptied all the money boxes in the entire public health system.”
By Arthur Allen -
Since Fall of ‘Roe,’ Self-Managed Abortions Have Increased
The percentage of people who say they’ve tried to end a pregnancy without medical assistance increased after "Roe v. Wade" was overturned. One of the most common reasons for seeking a self-managed abortion was privacy concerns.
By Sarah Varney -
Harris in the Spotlight
Episode 357For the 2024 campaign, Joe Biden is out, and Kamala Harris is in. As the vice president makes moves toward the top of the Democratic presidential ticket, health policy is resurging as a campaign issue. Meanwhile, Congress tries — and again fails — to make timely progress on the annual government spending bills as abortion issues cause delays. Alice Miranda Ollstein of Politico, Stephanie Armour of KFF Health News, and Rachel Cohrs Zhang of Stat join KFF Health News’ Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Anthony Wright, the new executive director of Families USA, about his plans for the organization and his history working with Harris on health topics.
-
World-Famous Wall Drug Isn’t Immune From Challenges Facing Rural Pharmacies
Even as part of a popular South Dakota tourist attraction, an independent pharmacy serving locals, remote ranchers, and sightseers struggles with staffing and insurer payments.
-
Louisiana Reclassifies Drugs Used in Abortions as Controlled Dangerous Substances
Louisiana lawmakers have added two drugs commonly used in pregnancy and reproductive health care to the state’s list of controlled dangerous substances, a move that has alarmed doctors in the state.
-
Why Millions Are Trying FDA-Authorized Alternatives to Big Pharma’s Weight Loss Drugs
Although Novo Nordisk and Lilly lump together the pharmacies that compound semaglutide and tirzepatide with internet cowboys selling fake drugs, there is a distinction. The FDA has offered Americans little clarity about the vast gray and black markets for the drugs.
By Arthur Allen -
Harris, Once Biden’s Voice on Abortion, Would Take an Outspoken Approach to Health
If she grabs the baton from President Joe Biden to become the new presumptive Democratic presidential nominee, Kamala Harris would widely be expected to take an aggressive stance in support of abortion access — hitting former President Donald Trump on an issue that could undermine his chances of victory.